PL423146A1 - Oleaceina do zastosowanie w prewencji miażdżycy - Google Patents

Oleaceina do zastosowanie w prewencji miażdżycy

Info

Publication number
PL423146A1
PL423146A1 PL423146A PL42314617A PL423146A1 PL 423146 A1 PL423146 A1 PL 423146A1 PL 423146 A PL423146 A PL 423146A PL 42314617 A PL42314617 A PL 42314617A PL 423146 A1 PL423146 A1 PL 423146A1
Authority
PL
Poland
Prior art keywords
oleacein
application
prevention
intended
atherosclerosis
Prior art date
Application number
PL423146A
Other languages
English (en)
Inventor
Agnieszka FILIPEK
Marek Naruszewicz
Original Assignee
Warszawski Univ Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Univ Medyczny filed Critical Warszawski Univ Medyczny
Priority to PL423146A priority Critical patent/PL423146A1/pl
Priority to PCT/PL2018/050023 priority patent/WO2019074383A1/en
Priority to CA3078910A priority patent/CA3078910A1/en
Priority to CN201880066501.6A priority patent/CN111212636A/zh
Priority to EP18461563.1A priority patent/EP3470069A1/en
Priority to US16/755,346 priority patent/US20200237703A1/en
Priority to JP2020541638A priority patent/JP2020536964A/ja
Publication of PL423146A1 publication Critical patent/PL423146A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem zgłoszenia jest zastosowanie oleaceiny do hamowania procesu tworzenia komórek piankowatych poprzez skuteczne hamowanie wychwytu oxLDL przez makrofagi, zwłaszcza poprzez obniżanie ekspresji makrofagowych receptorów zmiatających. Wywarzane zgodnie z wynalazkiem preparaty farmaceutyczne zawierające oleaceinę nadają się do stosowania w leczeniu lub zapobieganiu miażdżycy, w szczególności w prewencji wczesnych stanów miażdżycowych.
PL423146A 2017-10-12 2017-10-12 Oleaceina do zastosowanie w prewencji miażdżycy PL423146A1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL423146A PL423146A1 (pl) 2017-10-12 2017-10-12 Oleaceina do zastosowanie w prewencji miażdżycy
PCT/PL2018/050023 WO2019074383A1 (en) 2017-10-12 2018-05-30 OLEACEIN FOR USE IN THE PREVENTION OF ATHEROSCLEROSIS
CA3078910A CA3078910A1 (en) 2017-10-12 2018-05-30 Oleacein for use in atherosclerosis prevention
CN201880066501.6A CN111212636A (zh) 2017-10-12 2018-05-30 橄榄裂环烯醚萜用于动脉粥样硬化预防
EP18461563.1A EP3470069A1 (en) 2017-10-12 2018-05-30 Oleacein for use in atherosclerosis prevention
US16/755,346 US20200237703A1 (en) 2017-10-12 2018-05-30 Oleacein for use in atherosclerosis prevention
JP2020541638A JP2020536964A (ja) 2017-10-12 2018-05-30 アテローム性動脈硬化症予防における使用のためのオレアセイン

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL423146A PL423146A1 (pl) 2017-10-12 2017-10-12 Oleaceina do zastosowanie w prewencji miażdżycy

Publications (1)

Publication Number Publication Date
PL423146A1 true PL423146A1 (pl) 2019-04-23

Family

ID=62631043

Family Applications (1)

Application Number Title Priority Date Filing Date
PL423146A PL423146A1 (pl) 2017-10-12 2017-10-12 Oleaceina do zastosowanie w prewencji miażdżycy

Country Status (7)

Country Link
US (1) US20200237703A1 (pl)
EP (1) EP3470069A1 (pl)
JP (1) JP2020536964A (pl)
CN (1) CN111212636A (pl)
CA (1) CA3078910A1 (pl)
PL (1) PL423146A1 (pl)
WO (1) WO2019074383A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR20190100075A (el) * 2019-02-13 2020-09-16 Προκοπιος Παναγιωτη Μαγιατης Μεθοδος παραλαβης σεκοϊριδοειδων τυπου ελαιασινης και ελαιομισσιοναλης και παραγωγης των αντιστοιχων φαρμακευτικων παρασκευασματων τους

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL227843B1 (pl) * 2012-07-14 2018-01-31 Warszawski Uniwersytet Medyczny Zastosowanie Ligustrum vulgare L. do wytwarzania preparatu zawierającego oleaceinę
TWI679985B (zh) * 2014-10-16 2019-12-21 日商三得利控股股份有限公司 含有橄欖果實萃取物的Ｔｉｅ２活化劑

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KISS AK, MAŃK M, MELZIG MF, DUAL INHIBITION OF METALLOPEPTIDASES ACE AND NEP BY EXTRACTS, AND IRIDOIDS FROM LIGUSTRUM VULGARE L, 2008 *
NARUSZEWICZ M, CZERWIŃSKA ME, KISS AK, OLEACEIN. TRANSLATION FROM MEDITERRANEAN DIET TO POTENTIAL ANTIATHEROSCLEROTIC DRUG, 2015 *

Also Published As

Publication number Publication date
CN111212636A (zh) 2020-05-29
JP2020536964A (ja) 2020-12-17
WO2019074383A1 (en) 2019-04-18
CA3078910A1 (en) 2019-04-18
EP3470069A1 (en) 2019-04-17
US20200237703A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2018013983A (es) Inhibidores g12c de kras.
TN2017000009A1 (en) Spirocycloheptanes as inhibitors of rock.
PT3565520T (pt) Composições anidras de inibidores de mtor e métodos de utilização
JOP20190174B1 (ar) مثبطات jak1 انتقائية
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
UA113440C2 (xx) Сполуки тетрагідропіразолопіримідину
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
PH12017501095A1 (en) Piperidine derivatives as hdac1/2 inhibitors
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
PH12017500836A1 (en) Transdermal formulations
MX390051B (es) Antagonistas de ep4.
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
MA40583A (fr) Nouveaux activateurs de la guanylate cyclase soluble et leur utilisation
MA39824A (fr) Composés azole amido-substitués
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
MX2022016251A (es) Compuestos antagonistas receptores de somatostatina y metodos para utilizarlos.
MX2017012783A (es) Carbamatos de alquinilo sustituidos por xantina/carbamatos inversos como antagonistas de a2b.
IN2014CN03625A (pl)